Decibel Therapeutics

View All

Pharma News and updates for HUTCHMED, Cytokinetics, Astellas, Seagen, Nanoscope Therapeutics, Cabaletta Bio, Decibel Therapeutics
HUTCHMED’s NDA Submission to FDA for Fruquintinib; Cytokinetics to Discontinue ALS Drug Candidate Following Phase III Trial Failure; Enfortumab Vedotin + Pembrolizumab Approved for Urothelial Carcinoma; Nanoscope Gene Therapy Clears Phase II Retinitis Pigmentosa Trial; FDA Clearance to Cabaletta Bio’s IND Application for CABA-201 for SLE Treatment; European Orphan Drug Designation to Gene Therapy Candidate DB-OTO

HUTCHMED Completes Rolling Submission of NDA to FDA for Fruquintinib HUTCHMED (China) Limited announced the completion of the rolling submission of a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") for fruquintinib, its highly selective and potent oral inhibitor of VEGFR-1,...

Find More

age-related-hearing-loss-device-market-analysis
Age-related Hearing Loss Device Market Dynamics Expected to Step into Growth Quadrant

Age-related hearing loss (ARHL), also known as presbycusis, is a complicated disease that has been observed in tens of millions of people around the world. It is defined as a progressive, irreversible, and symmetrical bilateral neurosensory hearing loss caused by cochlea degeneration, in which sound-induced vibrati...

Find More